deltatrials

Icahn School of Medicine at Mount Sinai Clinical Trials

Sponsors / Icahn School of Medicine at Mount Sinai

Icahn School of Medicine at Mount Sinai is listed as the lead sponsor on 669 clinical trials registered with ClinicalTrials.gov. 138 trials are actively recruiting participants, 24 remain active without open enrollment, and 395 have concluded. 73 of these trials ended early via termination or withdrawal. The most common reasons cited for termination include slow or insufficient recruitment, funding constraints. The cumulative planned enrollment figure across all listed trials is 454,710 participants. All figures are drawn directly from ClinicalTrials.gov and updated as sponsors submit revisions.

669
Total Trials
138
Recruiting
24
Other Active
395
Completed
73
Terminated / Withdrawn
454,710
Total Enrollment

Termination reasons: Recruitment42% · Other33% · Funding11% · Efficacy8% · Safety3% · PI/or_Site1% · Regulatory1%

Recent Terminations

  • NCT06985342 Stopped Feb 2026
    Migraine Headaches
    "Study closing at current site. Study to start as new at different site."
  • NCT06240117 Phase NA Stopped Jun 2025
    Peripartum Anemia
    "Under enrollment"
  • NCT05879458 Phase PHASE2 Stopped Jun 2025
    CTCL
    "No significant improvement in disease as graded by our assessments."
  • NCT06313632 Phase PHASE3 Stopped Mar 2025
    Pleural Disease
    "interim, lack of obvious benefit"
  • NCT06013371 Phase PHASE2 Stopped Feb 2025
    Papulopustular Rosacea
    "The study ended early because interim analysis showed no significant difference between the active and placebo arms."
  • NCT06167304 Phase NA Stopped Feb 2025
    Chronic Pain
    "Sponsor halted funding"
  • NCT05630924 Phase NA Stopped Dec 2024
    Cardiovascular Health
    "Not meeting recruitment targets"
  • NCT05777187 Phase NA Stopped Aug 2024
    Cognitive Impairment
    "Study enrollment closed due to low enrollment."
  • NCT06110806 Phase NA Stopped Jul 2024
    Avoidant Restrictive Food Intake Disorder
    "Lack of agreement for risk mitigation plan"
  • NCT05427916 Phase NA Stopped Feb 2023
    Diabetes
    "Site decided not to continue"

Active Trials (24 total)

See all 24 active trials

Top Conditions

Top Locations